Purpose
The Sunshine Act promotes transparency in financial relationships between healthcare providers and manufacturers of drugs, devices, biologics, and medical supplies. The goal is to:
- Increase public awareness of financial relationships
- Reduce potential conflicts of interest
- Support informed healthcare decision-making
- Provide data for research on healthcare quality and costs
Sunshine Act compliance software plays a critical role in helping life sciences companies meet federal and state reporting requirements tied to healthcare provider (HCP) spend. With the Physician Payments Sunshine Provisions included in health care reform legislation, the federal government joined six states in mandating the reporting of expenditures made by life science companies to HCP identified with National Provider Identifiers (NPI).
The Physician Payment Sunshine Provisions were included in the Patient Protection and Affordable Care Act of 2010 (H.R. 3590, section 6002), referred to throughout this document as the Sunshine Act. The legislation was signed into law on March 23, 2010. Beginning on January 1, 2012, all U.S. manufacturers of drug, device, biologics, and medical supplies covered under Medicare, Medicaid, or SCHIP were required to record all transfers of value on an annual basis.
This information must be submitted to the U.S. Department of Health and Human Services and is published annually on a public website as part of ongoing Sunshine Act reporting requirements.
Implementation Timeline
- March 23, 2010: Act signed into law
- February 1, 2013: Final rule published
- August 1, 2013: Data collection began
- March 31, 2014: First annual reports submitted to CMS
- September 30, 2014: First public data release (covering 2013 data)
- 2021: Program expanded under SUPPORT Act
- 2022-2024: Multiple regulatory updates and refinements
Healthcare Provider Recipients and Reportable Activity
Face-to-face sales and promotional activities directed toward HCPs (commonly known as “detailing”) represent one of the largest marketing expenditures in the life sciences industry, second only to pharmaceutical samples.
Where a payment is related to marketing, education, or research specific to a covered drug, device, biologic, or medical supply, companies are required to report specific data under the Sunshine Act compliance rules.
Problem Statement
A company affected by the Sunshine Act is likely tracking spending associated with food, entertainment and gifts incurred in the direct marketing to HCPs as part of their expense reporting process.
The challenge arises when those expenses must be tracked and reported at the level of detail required by Sunshine Act compliance regulations.
The volume of transactions, the need to allocate costs across multiple recipients, and the complexity of state-specific rules make manual or loosely controlled processes risky. The potential for poor data quality, due to tracking many small transactions divided by a large list of recipients, can impact both operational efficiency and compliance.
Clear, consistent, and auditable data is essential to assisting the healthcare industry in managing the burden of reporting posed by the Sunshine Act.
Reportable transfers of value include:
- Direct compensation
- Food
- Entertainment
- Gifts
- Travel
- Consulting fees
- Honoraria
- Education
- Research
- Grants
- Charitable contributions
- Royalties or licenses
- Current or prospective ownership or investment interests
- Compensation for serving as a faculty member or as a speaker for a continuing medical education program
- Any other transfer of value as defined by the Secretary of Health and Human Service
Required recipient data includes:
- Name
- Business Name
- Address
- National Provider Identifier (NPI)
- Value of the payment or transfer of value
- Dates of the payments or transfers
Description of the form of payment or transfer of value